Patents by Inventor Dmitriy Zamarin
Dmitriy Zamarin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200061184Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.Type: ApplicationFiled: May 11, 2018Publication date: February 27, 2020Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme Corp.Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Svetlana Sadekova, Rachel Allison Altura, Uyen Phan, Brian B. Haines, Jedd D. Wolchok
-
Patent number: 10251922Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: GrantFiled: October 20, 2017Date of Patent: April 9, 2019Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Jedd D. Wolchok
-
Publication number: 20180280455Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: October 20, 2017Publication date: October 4, 2018Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Publication number: 20180256655Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: October 20, 2017Publication date: September 13, 2018Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Patent number: 10035984Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: GrantFiled: November 16, 2015Date of Patent: July 31, 2018Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Publication number: 20180078592Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: May 5, 2017Publication date: March 22, 2018Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, Memorial Sloan Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Publication number: 20160068823Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: ApplicationFiled: November 16, 2015Publication date: March 10, 2016Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Publication number: 20160015760Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: March 4, 2014Publication date: January 21, 2016Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, Memorial Sloan Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Patent number: 9217136Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: GrantFiled: October 22, 2013Date of Patent: December 22, 2015Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Publication number: 20140271677Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Publication number: 20140044678Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: ApplicationFiled: October 22, 2013Publication date: February 13, 2014Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MOUNT SINAI SCHOOL OF MEDICINEInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Patent number: 8591881Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: GrantFiled: February 5, 2010Date of Patent: November 26, 2013Assignees: Mount Sinai School of Medicine, Memorial Sloan-Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Publication number: 20120058141Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: ApplicationFiled: February 5, 2010Publication date: March 8, 2012Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong